Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
Study Details
Study Description
Brief Summary
The objectives of this trial are to evaluate the safety and tolerability of perfluorohexyloctane (NOV03) ophthalmic solution during long-term use in subjects with Dry Eye Disease (DED) associated with MGD (Meibomian Gland Dysfunction).
Further objective is to evaluate the efficacy of perfluorohexyloctane (NOV03) solution during long-term use in subjects with DED associated with MGD.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: NOV03 4 times daily (QID) 100% Perfluorohexyloctance solution 4 times daily (QID) |
Drug: NOV03
100% Perfluorohexyloctane
|
Outcome Measures
Primary Outcome Measures
- Ocular and non-ocular adverse events [12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed ICF (Informed Consent Form)
-
Subject-reported history of Drye Eye Disease (DED) in both eyes
-
Ability and willingness to follow instructions, including participation in all study assessments and visits
Exclusion Criteria:
-
Women who are pregnant, nursing or planning pregnancy
-
Unwillingness to submit a blood pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control
-
Clinically significant slit-lamp findings or abnormal lid anatomy at screening
-
Ocular/peri-ocular malignancy
-
History of herpetic keratitis
-
Active ocular allergies or ocular allergies that are expected to be active during the study
-
Ongoing ocular or systemic infection
-
Wear contact lenses within 1 month prior to screening or anticipated use of contact lenses during the study
-
Intra-ocular surgery or ocular laser surgery within the previous 6 months, or have planned ocular and/or lid surgeries over the study period
-
Presence of uncontrolled systemic diseases
-
Presence of known allergy and/or sensitivity to the study drug or saline components
-
Use of any topical steroids treatments, topical cyclosporine, lifitegrast, serum tears or topical anti-glaucoma medication within 2 months prior to screening
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Bausch Site 124 | Birmingham | Alabama | United States | 35233 |
2 | Bausch Site 125 | Scottsdale | Arizona | United States | 85254 |
3 | Bausch Site 110 | Glendale | California | United States | 91204 |
4 | Bausch Site 121 | Long Beach | California | United States | 90805 |
5 | Bausch Site 102 | Mission Hills | California | United States | 91345 |
6 | Bausch Site 101 | Newport Beach | California | United States | 92663 |
7 | Bausch Site 116 | Rancho Cordova | California | United States | 95670 |
8 | Bausch Site 103 | Torrance | California | United States | 90505 |
9 | Bausch Site 123 | Torrance | California | United States | 90505 |
10 | Bausch Site 127 | Danbury | Connecticut | United States | 06810 |
11 | Bausch Site 129 | Fort Myers | Florida | United States | 33901 |
12 | Bausch Site 115 | Jacksonville | Florida | United States | 32256 |
13 | Bausch Site 106 | Largo | Florida | United States | 33773 |
14 | Bausch Site 117 | Tampa | Florida | United States | 33603 |
15 | Bausch Site 108 | Lake Villa | Illinois | United States | 60046 |
16 | Bausch Site 112 | Indianapolis | Indiana | United States | 46260 |
17 | Bausch Site 119 | Edgewood | Kentucky | United States | 41017 |
18 | Bausch Site 126 | Winchester | Massachusetts | United States | 01890 |
19 | Bausch Site 113 | Kansas City | Missouri | United States | 64111 |
20 | Bausch Site 111 | Saint Louis | Missouri | United States | 63131 |
21 | Bausch Site 128 | Slingerlands | New York | United States | 12159 |
22 | Bausch Site 114 | Raleigh | North Carolina | United States | 27603 |
23 | Bausch Site 122 | Cranberry Township | Pennsylvania | United States | 16066 |
24 | Bausch Site 107 | Memphis | Tennessee | United States | 38119 |
25 | Bausch Site 109 | Nashville | Tennessee | United States | 37205 |
26 | Bausch Site 120 | El Paso | Texas | United States | 79902 |
27 | Bausch Site 104 | Lakeway | Texas | United States | 78738 |
28 | Bausch Site 118 | San Antonio | Texas | United States | 78229 |
Sponsors and Collaborators
- Bausch & Lomb Incorporated
Investigators
- Study Director: Johnson Varughese, Bausch Health
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NVU-004 (Kalahari)